MA32550B1 - Derives de benzazepine et leur utilisation comme antagonistes des recepteurs h3 de l'histamine - Google Patents

Derives de benzazepine et leur utilisation comme antagonistes des recepteurs h3 de l'histamine

Info

Publication number
MA32550B1
MA32550B1 MA33600A MA33600A MA32550B1 MA 32550 B1 MA32550 B1 MA 32550B1 MA 33600 A MA33600 A MA 33600A MA 33600 A MA33600 A MA 33600A MA 32550 B1 MA32550 B1 MA 32550B1
Authority
MA
Morocco
Prior art keywords
alkyl
cycloalkyl
heterocyclyl
aryl
halo
Prior art date
Application number
MA33600A
Other languages
Arabic (ar)
English (en)
Inventor
Parminder Kaur Pooni
Kevin John Merchant
Catrina Morvern Kerr
Stuart Richard Crosby
Tomohiro Okawa
Mitsuru Sasaki
Mika Gotou
Graham Andrew Showell
Martin Richard Teall
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0813254A external-priority patent/GB0813254D0/en
Priority claimed from GB0905231A external-priority patent/GB0905231D0/en
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA32550B1 publication Critical patent/MA32550B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

L'invention porte sur un composé représenté par la formule (1) dans laquelle : r1 est un groupe choisi parmi cycloalkyle en c3-8, alkyle en c1-6, alkylène en c1-6-cycloalkyle en c3-8, chacun de ces groupes pouvant éventuellement être substitué par alkyle en c1-6, halogène, halo-alkyle en c1-6 ou or15, ou r1 représente hétérocyclyle, éventuellement substitué par alkyle en c1-6, halo-alkyle en c1-6 ou or15; n vaut 0, 1, 2, 3 ou 4, le groupe alkylène -(ch2)n- formé de cette façon étant éventuellement substitué par un groupe choisi parmi alkyle en c1-4, cycloalkyle en c3-8 et arylsulfonyle; a est un groupe choisi parmi -n(r2)co-, -con(r2)-, -oc(o)-, -c(o)o-, -co-, -c(r2)(or3)-, -c(=n-o-r3)-, -c(=cr2r3)-, -cycloalkylène en c3-8-,-c(r2)(halo-alkyle en c1-6)-, alkylène en c1-4 et -c(or3)(halo-alkyle en c1-6)-; r2 et r3 sont chacun choisis indépendamment parmi h, alkyle en c1-6 et cycloakyle en c3-8 ou, lorsque a représente -n(r2)co- et x est absent, r2 peut former, conjointement avec l'atome d'azote adjacent et z, un groupe hétérocyclyle contenant n, qui peut éventuellement être substitué; x est absent ou représente alkylène en c1-4 ou alcénylène en c2-4, dont chacun peut éventuellement être substitué par un ou plusieurs groupes alkyle en c1-4, or16, halogène ou halo-alkyle en c1-6; z est choisi parmi aryle, hétéroaryle, cycloalkyle en c3-8 et hétérocyclyle, dont chacun peut éventuellement être substitué par un groupe choisi parmi -y-aryle, -y-hétéroaryle, -y-cycloalkyle en c3-8 et -y-hétérocyclyle, ou, lorsque x est présent, z peut être h ou, lorsque x est absent et a représente -c(r2)(or3)- ou -n(r2)co-, z peut être h ou, lorsque a représente -n(r2)co- et x est absent, z peut former, conjointement avec l'atome d'azote adjacent et r2, un groupe hétérocyclyle contenant n qui peut éventuellement être substitué, dans lequel, lorsque a représente -co-, z est lié à x ou a par l'intermédiaire d'un atome de carbone, et où, lorsque a représente -n(r2)co- et z représente h, r1 représente cycloalkyle en c3-8; et y représente une liaison, alkylène en c1-6, co, nr14, co-alcénylène en c2-6, o, so2 ou nhco-alkylène en c1-6; lesdits groupes cycloalkyle, aryle, hétéroaryle et hétérocyclyle z pouvant être éventuellement substitués par un ou plusieurs substituants qui peuvent être identiques ou différents, et qui sont choisis parmi halogène, halo-alkyle en c1-6, hydroxy, cyano, nitro, =o, -r4, -co2r4, -cor4, -nr5r6, -alkyl en c1-6-nr5r6, -cycloakyle en c3-8'nr5r6, -conr12r13, -nr12cor13, -nr5so2r6, -oconr5r6, -nr5co2r6, -nr4conr5r6 ou -so2nr5r6-shr8, -alkyl-or8, -sor8, -or9, -so2r9, -oso2r9, -alkyl-so2r9, -alkyl-conhr9, -alkyl-sonhr9, -alkyl-cor1o, -co-alkyl-r1o, -o-alkyl-r11 (où r4, r5 et r6 représentent indépendamment hydrogène, alkyle en c1-6, -cycloalkyle en c3-8, -alkylène en c1-6-cycloalkyle en c3-8, aryle, hétérocyclyle ou hétéroaryle, où r8 représente alkyle en c1-6, où r9 représente alkyle en c1-6 ou aryle, où r10 représente aryle, où r11 représente cycloalkyle en c3-8 ou aryle, r12, r13, r14, r15 et r16 représentent chacun indépendamment h ou alkyle en c1-6, et où -nr5r6 et -nr12r13 peuvent représenter un groupe hétérocyclyle contenant de l'azote); où lesdits groupes r4, r5, r6, r8, r9, r10 et r11 peuvent être éventuellement substitués par un ou plusieurs substituants qui peuvent être identiques ou différents et qui sont choisis dans le groupe constitué par halogène, hydroxy, alkyle en c1-6, alcoxy en c1-6, cyano, amino, =o ou trifluorométhyle; et où les substituants de z choisis parmi -y-aryle, -y-hétéroaryle, -y-cycloalkyle en c3-8 et -y-hétérocyclyle peuvent être éventuellement substitués par un ou plusieurs substituants choisis parmi =o, hydroxy, cyano, nitro, halogène, halo-alkyle en c1-6 et alkyle en c1-6; et où, lorsque a représente alkylène en c1-4, ledit groupe cycloalkyle, aryle, hétéroaryle ou hétérocyclyle z (tel qu'un groupe hétérocyclyle z) est substitué au moins par hydroxy, cf3 ou =0; et où, lorsque a représente con(r2), n
MA33600A 2008-07-18 2011-02-10 Derives de benzazepine et leur utilisation comme antagonistes des recepteurs h3 de l'histamine MA32550B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0813254A GB0813254D0 (en) 2008-07-18 2008-07-18 Compounds and their use
GB0905231A GB0905231D0 (en) 2009-03-26 2009-03-26 Compounds and their use
PCT/GB2009/001774 WO2010007382A1 (fr) 2008-07-18 2009-07-17 Dérivés de benzazépine et leur utilisation comme antagonistes des récepteurs h3 de l'histamine

Publications (1)

Publication Number Publication Date
MA32550B1 true MA32550B1 (fr) 2011-08-01

Family

ID=41051104

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33600A MA32550B1 (fr) 2008-07-18 2011-02-10 Derives de benzazepine et leur utilisation comme antagonistes des recepteurs h3 de l'histamine

Country Status (19)

Country Link
US (1) US20110124626A1 (fr)
EP (1) EP2326625A1 (fr)
JP (1) JP2011528341A (fr)
KR (1) KR20110036044A (fr)
CN (1) CN102099339A (fr)
AU (1) AU2009272486A1 (fr)
CA (1) CA2731196A1 (fr)
CL (1) CL2011000043A1 (fr)
CO (1) CO6341614A2 (fr)
CR (1) CR20110049A (fr)
DO (1) DOP2011000015A (fr)
EA (1) EA201170196A1 (fr)
EC (1) ECSP11010838A (fr)
GE (1) GEP20125590B (fr)
IL (1) IL210722A0 (fr)
MA (1) MA32550B1 (fr)
MX (1) MX2011000460A (fr)
PE (1) PE20110408A1 (fr)
WO (1) WO2010007382A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2655604C (fr) 2006-06-23 2016-08-09 Abbott Laboratories Derives de cyclopropylamine
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
EP3725775A1 (fr) 2009-02-17 2020-10-21 Syntrix Biosystems, Inc. Pyridine- et pyrimidinecarboxamides comme modulateurs du cxcr2
US8895588B2 (en) 2009-03-26 2014-11-25 Takeda Pharmaceutical Company Limited Pyrazole compound
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2011083316A1 (fr) * 2010-01-08 2011-07-14 Takeda Pharmaceutical Company Limited Dérivés de la benzazépine destinés à traiter des troubles du système nerveux central
WO2011083315A1 (fr) 2010-01-08 2011-07-14 Takeda Pharmaceutical Company Limited Composés et leur utilisation
WO2011083314A1 (fr) * 2010-01-08 2011-07-14 Takeda Pharmaceutical Company Limited Dérivés de la benzazépine destinés à traiter des troubles du système nerveux central
JP5784110B2 (ja) 2010-05-11 2015-09-24 サノフイ 置換されたｎ−ヘテロアリールテトラヒドロ−イソキノリン誘導体、その製造及び治療上の使用
EP2569303A1 (fr) 2010-05-11 2013-03-20 Sanofi Dérivés n-alkyl et n-acyl tétrahydro-isoquinoline substitués, procédé de préparation et application thérapeutiques associés
TW201202251A (en) 2010-05-11 2012-01-16 Sanofi Aventis Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
AR081383A1 (es) 2010-05-11 2012-08-29 Sanofi Aventis N-heteroaril bipirrolidin carboxamidas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de enfermedades del sistema nervioso central.
JP2013529198A (ja) 2010-05-11 2013-07-18 サノフイ 置換されたｎ−ヘテロシクロアルキルビピロリジニルフェニルアミド誘導体、その製造及び治療上の使用
TW201206939A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
AU2011293612B2 (en) * 2010-08-23 2015-11-26 Syntrix Biosystems Inc. Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators
WO2012037258A1 (fr) 2010-09-16 2012-03-22 Abbott Laboratories Procédés de préparation de dérivés cyclopropyliques substitués en 1,2
WO2013151982A1 (fr) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Méthodes et composés utiles pour traiter le prurit, et procédés d'identification desdits composés
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
CN106061480B (zh) 2013-12-30 2020-02-28 莱福斯希医药公司 治疗性抑制性化合物
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
BR112017000816A2 (pt) * 2014-07-16 2017-12-05 Lifesci Pharmaceuticals Inc compostos inibitórios terapêuticos
US10183940B2 (en) * 2014-11-14 2019-01-22 Boehringer Ingelheim International Gmbh Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (SSTR4) agonists
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
EP3481391A4 (fr) 2016-07-11 2020-03-11 Lifesci Pharmaceuticals, Inc. Composés inhibiteurs thérapeutiques
GB201617758D0 (en) 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
AU2018367909B2 (en) 2017-11-17 2022-03-10 Cellix Bio Private Limited Compositions and methods for the treatment of eye disorders
CN114736195B (zh) * 2022-03-01 2022-11-15 天水师范学院 一种氧硫杂环戊烷-苯并香豆素化合物及其制备方法和作为荧光探针的用途
WO2024052684A1 (fr) 2022-09-09 2024-03-14 MyricX Pharma Limited Conjugué anticorps-médicament comprenant un inhibiteur de nmt et son utilisation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW197435B (fr) * 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
ATE479429T1 (de) * 2000-04-28 2010-09-15 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
CA2408913A1 (fr) * 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
CN1254474C (zh) * 2000-11-14 2006-05-03 史密斯克莱·比奇曼公司 作为多巴胺D<sub>3</sub>受体调节剂(精神抑制药)的四氢苯并氮杂䓬衍生物
WO2004113300A1 (fr) * 2003-06-23 2004-12-29 Ono Pharmaceutical Co., Ltd. Nouveau compose heterocyclique tricyclique
JPWO2005040135A1 (ja) * 2003-10-24 2007-03-08 小野薬品工業株式会社 抗ストレス薬およびその医薬用途
GB0329214D0 (en) * 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
ES2375963T3 (es) * 2003-12-18 2012-03-07 Abbott Gmbh & Co. Kg Tetrahidrobenzacepinas y su uso en la modulación del receptor d3 de la dopamina.
US20050137186A1 (en) * 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
WO2005063241A1 (fr) * 2003-12-26 2005-07-14 Ono Pharmaceutical Co., Ltd. Agent pour prevenir et/ou de traiter des maladies faisant intervenir un recepteur de benzodiazepine mitochondrial
GB0405628D0 (en) * 2004-03-12 2004-04-21 Glaxo Group Ltd Novel compounds
EP1756094A1 (fr) * 2004-06-18 2007-02-28 Glaxo Group Limited 3-cycloalkylbenzazepines utilisees en tant qu'antagonistes de h3 l'histamine
JP5315611B2 (ja) * 2004-06-23 2013-10-16 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその用途
GB0418267D0 (en) * 2004-08-16 2004-09-15 Glaxo Group Ltd Novel compounds
US8557812B2 (en) * 2004-08-20 2013-10-15 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof
DE102006039003A1 (de) * 2006-08-19 2008-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Verbindungen
US20080159958A1 (en) * 2006-12-27 2008-07-03 Abbott Laboratories Determination of histamine-3 bioactivity
JP5557832B2 (ja) * 2008-03-18 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 置換４−ヒドロキシピリジン−５−カルボキサミド

Also Published As

Publication number Publication date
GEP20125590B (en) 2012-07-25
MX2011000460A (es) 2011-03-15
PE20110408A1 (es) 2011-06-22
IL210722A0 (en) 2011-03-31
CA2731196A1 (fr) 2010-01-21
ECSP11010838A (es) 2011-05-31
EP2326625A1 (fr) 2011-06-01
CL2011000043A1 (es) 2011-10-28
WO2010007382A8 (fr) 2010-03-18
CN102099339A (zh) 2011-06-15
EA201170196A1 (ru) 2011-12-30
US20110124626A1 (en) 2011-05-26
CO6341614A2 (es) 2011-11-21
AU2009272486A1 (en) 2010-01-21
KR20110036044A (ko) 2011-04-06
WO2010007382A1 (fr) 2010-01-21
DOP2011000015A (es) 2011-04-15
CR20110049A (es) 2011-06-22
JP2011528341A (ja) 2011-11-17

Similar Documents

Publication Publication Date Title
MA28024A1 (fr) Derives de (thio) carbamoyl-cyclohexane utilises en tant qu&#39;antagonistes des recepteurs d3/d2
WO2010007382A8 (fr) Dérivés de benzazépine et leur utilisation comme antagonistes des récepteurs h3 de l&#39;histamine
ATE512955T1 (de) Stickstoffhaltige heterozyklische derivate und medikamente die diese enthalten
EP0776884A4 (fr) Derive d&#39;amide substitue
ATE313535T1 (de) Pyrazinyl-piperazin-verbindungen, ihre anwendung und herstellung
EA200600990A1 (ru) Производные бензосульфониламинопиридин-2-ила и родственные соединения в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы 1 типа (11-бета-hsd-1) для лечения диабета и ожирения
CA2682329A1 (fr) Derives d&#39;imidazopyridine substitues comme antagonistes du recepteur de la melanocortine -4
EP1600442A4 (fr) Derives d&#39;heteroarylcarbamoylbenzene
MX2012003499A (es) Inhibidores de demetilasa-1 especificos de lisina y su uso.
HRP20100650T1 (hr) Derivati maleimida, farmaceutski pripravci i postupci lijecenja raka
SE0202134D0 (sv) Therapeutic agents
TW200744587A (en) Azaindole derivatives exhibiting PGD2 receptor antagonism
HRP20090250T1 (hr) Kondenzirani heterociklički spojevi i njihova upotreba kao inhibitora hcv polimeraze
RU2010119447A (ru) Новые соединения миметики обратного поворота и их применение
HRP20080541T3 (en) Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
JP2012509940A5 (fr)
TW200800938A (en) Indole carboxylic acid derivatives exhibiting PGD2 receptor antagonism
ATE524433T1 (de) Trpv1 agonisten , zubereitungen die diese enthalten und ihre anwendung
AR038886A1 (es) Amidas heterociclicas, inhibidores de actividad de glucogeno fosforilasa
MX2010003148A (es) Procedimiento para la preparacion de diamidas de acido sulfonico.
DE60014394D1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
PE20091552A1 (es) Farmacoforos duales - antagonistas muscarinicos de pde4
MXPA06010880A (es) Compuestos de benzopirano triciclico como agentes anti-arritmicos.
PE20001384A1 (es) Derivados de acetamida no peptidicos como antagonistas de receptor de nk1
RU2007101497A (ru) Алкилзамещенные индолхиноксалины